stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
24.58
1.45
−5.57%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Shares outstanding
Caris Life Sciences,�Inc.'s shares outstanding at the end of fiscal 2025 was $167.2M, up 371.0% from $35.5M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $295.1M. Caris Life Sciences,�Inc. ranks 24th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $167.2M | 371.04% |
| FY2024 | $35.5M | 1.59% |
| FY2023 | $34.9M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $295.1M | 4.33% |
| Jun 2026 | $282.9M | 0.12% |
| Mar 2026 | $282.6M | (4.57%) |
| Dec 2025 | $296.1M | (0.38%) |
| 5 more quarters | Free account |
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| CAI Caris Life Sciences,�Inc. | $295.1M |
| TGTX TG Therapeutics, Inc. compare | $157.3M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| PTGX Protagonist Therapeutics, Inc. compare | $71.0M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $30.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Book value per share
- The full statement